Characterization of [3H]-Nicotine Binding in Rodent Brain and Comparison with the Binding of Other Labelled Nicotinic Ligands

  • C. Larsson
  • A. Nordberg
Part of the Advances in Behavioral Biology book series (ABBI, volume 30)


Nicotine can induce diverse pharmacological effects on the central nervous system (CNS), including alterations of spontaneous motoric activity, behavior and memory, antinociceptive effects, hypothermia, antidiuresis and convulsions (11, 15, 23). It is also considered to be a dependence-producing drug (4) and it is widely assumed that the nicotine content of tobacco smoke may play an important role in the development of the tobacco smoking habit (3, 5). Although it is usually assumed that at least some of these effects of nicotine are mediated by nicotinic receptors on neurons in the CNS, there is today no direct evidence for this assumption. It is of interest to note, however, that in some recent experimental studies a change in nicotine-like binding sites in the brain has been observed following chronic administration of nicotine (8, 26).


Nicotinic Receptor Brain Homogenate Scatchard Plot Rodent Brain Mouse Hippocampus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abood, L.G., Grassi, S. and Costanza, M. (1983): FEBS Lett. 157: 147–149.CrossRefGoogle Scholar
  2. 2.
    Abood, L.G., Reynolds, D.T. and Bidlack, J.M. (1980): Life Sci. 27: 1307–1314.CrossRefGoogle Scholar
  3. 3.
    Armitage, A.K., Hall, G.H. and Morrison, C.F. (1968): Nature 217: 331–334.CrossRefGoogle Scholar
  4. 4.
    Balfour, D.J.K. (1982): Pharmac. Ther. 15: 239–250.CrossRefGoogle Scholar
  5. 5.
    Battig, K. (1981): Trends in Pharmacol. Sci. 2: 145–147.Google Scholar
  6. 6.
    Costa, L.G. and Murphy, S.D. (1983): J. Pharmacol. Exp. Ther. 226: 392–397.Google Scholar
  7. 7.
    Eterovic, V.A. and Bennet, E.L. (1974): Biochim. Et Biophys. Acta 362:346–355.CrossRefGoogle Scholar
  8. 8.
    Falkeborn, Y., Larsson, C. and Nordberg, A. (1981): Drug and Alcohol Dependence 8: 51–60.CrossRefGoogle Scholar
  9. 9.
    Fambrough, D.M. (1979): Physiol. Rev. 59: 165–226.Google Scholar
  10. 10.
    Gray, E.G. and Whittaker, V.P. (1962): J. Anat. 96: 79–89.Google Scholar
  11. 11.
    Larsson, C. and Nordberg, A. (1980): In Neurotransmitters and their Receptors (eds) U.Z. Littauer, Y. Dudai, I. Silman, V.I. Teichberg and Z. Vogel, John Wiley & Sons Ltd., pp. 297–301.Google Scholar
  12. 12.
    Larsson, C. and Nordberg, A. (1985): J. Neurochem. 45: 24–31.CrossRefGoogle Scholar
  13. 13.
    Lowy, J., McGregor, J., Rosenstone, J. and Schmidt, J. (1976): Biochem. 15: 1522–1527.CrossRefGoogle Scholar
  14. 14.
    Mangan, G.L. and Golding, J.F. (1984): In: The Psychopharmacology of Smoking, Cambridge University Press, pp. 97–140.Google Scholar
  15. 15.
    Mansner, R. (1972): Ann. Med. Exp. et Biol. Fenniae 50: 205–212.Google Scholar
  16. 16.
    Marks, M.J. and Collins, A.C. (1982): Mol. Pharmacol. 22 554–564.Google Scholar
  17. 17.
    Martin, B.R. and Aceto, M.D. (1981): Neurosci. Biobehay. Reviews 5: 473–478.CrossRefGoogle Scholar
  18. 18.
    Morley, B.J. (1981): Pharmac. Ther. 15: 111–122.CrossRefGoogle Scholar
  19. 19.
    Morley, B.J., Farley, G.R. and Javel, E. (1983): Trends in Pharmacol. Sci. 4: 225–227.Google Scholar
  20. 20.
    Morley, B.J. and Kemp, G.E. (1981): Brain Research 3: 81–104.CrossRefGoogle Scholar
  21. 21.
    Morley, B.J., Kemp, G.E. and Salvaterra, P. (1979): Life Sci. 24: 859–872.CrossRefGoogle Scholar
  22. 22.
    Nordberg, A. and Larsson, C. (1981): In Cholinergic Mechanisms: Phylogenetic Aspects. Central and Peripheral Synapses and Clinical Significance (eds) G. Pepeu and A. Ladinsky, Plenum Press, New York, pp. 819–824.Google Scholar
  23. 23.
    Nordberg, A. and Sundwall, A. (1983): Acta pharmacol et toxicol. 52: 341–347.CrossRefGoogle Scholar
  24. 24.
    Oswald, R.E. and Freeman, J.A. (1981): Neuroscience 6: 1–14.CrossRefGoogle Scholar
  25. 25.
    Romano, C. and Goldstein, A. (1980): Science 210: 647–649.CrossRefGoogle Scholar
  26. 26.
    Schwartz, R.D. and Kellar, K.J. (1983): Science 220: 214–216.CrossRefGoogle Scholar
  27. 27.
    Sershen, H., Reith, M.E.A., Lajtha, A. and Gennaro, J. Jr. (1981): J. Recept. Research 2: 1–15.Google Scholar
  28. 28.
    Terenius, L. and Wahlstrbm, A. (1976): Eur. J. Pharmacol. 40: 241–248.CrossRefGoogle Scholar
  29. 29.
    Yoshida, K. and Imura, H. (1979): Brain Research 172: 453–459.CrossRefGoogle Scholar
  30. 30.
    Yoshida, K., Engel, J. and Lilijequist, S. (1982): Arch. Pharmacology 321: 74–76.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • C. Larsson
    • 1
  • A. Nordberg
    • 1
  1. 1.Department of PharmacologyUppsala University Biomedical CenterUppsalaSweden

Personalised recommendations